Elzovantinib

DB18918InvestigationalSmall molecule

Elzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).

Formula / weight: C₂₀H₂₀FN₇O₂ · 409.425 g/mol (avg)
Also known as: 1,15-Etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile, 3-amino-14-ethyl-11-fluoro-4,5,6,7,13,14-hexahydro-7-methyl-4-oxo-, (7S)-
Code names: TPX-0022

Resolves to

Compound

UNIITTY12Q00LYCAS2271119-26-5

Structure

InChIKeyUUDPUQDMSHQSKH-NSHDSACASA-NSMILESCCN1CC2=C(O[C@@H](C)CNC(=O)C3=C4N=C1C=CN4N=C3N)C=CC(F)=C2C#N

Targets

P07333CSF1RP08581METP12931SRC

What you can answer from here — as of April 23, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elzovantinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account